Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy

Abstract The multifaceted chemo-immune resistance is the principal barrier to achieving cure in cancer patients. Identifying a target that is critically involved in chemo-immune-resistance represents an attractive strategy to improve cancer treatment. iRhom1 plays a role in cancer cell proliferation...

Full description

Bibliographic Details
Main Authors: Zhangyi Luo, Yixian Huang, Neelu Batra, Yuang Chen, Haozhe Huang, Yifei Wang, Ziqian Zhang, Shichen Li, Chien-Yu Chen, Zehua Wang, Jingjing Sun, Qiming Jane Wang, Da Yang, Binfeng Lu, James F. Conway, Lu-Yuan Li, Ai-Ming Yu, Song Li
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-44572-6

Internet

https://doi.org/10.1038/s41467-023-44572-6

Similar Items